Development of venetoclax for therapy of lymphoid malignancies

B-cell lymphoma-2 (BCL-2) family dysfunction and impairment of apoptosis are common in most B-cell lymphoid malignancies. Venetoclax (Venclexta™, formerly ABT-199, GDC-0199) is a highly selective BCL-2 inhibitor, which mimics its BCL-2 homology 3-domain to induce apoptosis. It was approved for treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Huayuan, Almasan, Alexandru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352161/
https://www.ncbi.nlm.nih.gov/pubmed/28331288
http://dx.doi.org/10.2147/DDDT.S109325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352161/
https://www.ncbi.nlm.nih.gov/pubmed/28331288
http://dx.doi.org/10.2147/DDDT.S109325

Ejemplares similares